Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efbemalenograstim alfa for preventing neutropenia in solid tumors
NCT06649448Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label trial of efbemalenograstim alfa in chemotherapy-induced neutropenia (CIN) (3 cohorts), sponsored by Shandong Cancer Hospital. Primary endpoint: The incidence rate of >= Grade 3 neutropenia in the first chemotherapy cycle. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
efbemalenograstim alfa
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT06649448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649448.